Purified anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Raised against granulocytes of mouse origin

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography.

Concentration

0.5 mg/ml

Storage & Handling

The Ly-6G/Ly-6C antibody solution should be stored undiluted between 2°C and 8°C.

Application

FC - Quality tested
IP, IHC, WB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C¹⁹. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A8¹⁹. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.4²⁰.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity², in vivo depletion^3-5,9, immunoprecipitation¹, immunohistochemical staining⁶ (including paraffin-embedded sections^9,16,33-35, acetone-fixed frozen sections¹¹ and zinc-fixed sections¹⁵), and Western blotting⁷. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)²⁰.

Special Note: For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).

Application References

(PubMed link indicates BioLegend citation)

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)

Product Citations

1. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
2. Ramirez-Moral I, et al. 2021. J Pathol. 253:374. PubMed
3. Weidner H, et al. 2020. JCI Insight. 5:00. PubMed
4. Matsuno Y, et al. 2007. Am J Respir Crit Care Med. 176:1015. PubMed
5. Li Y, et al. 2022. Int J Biol Sci. 18:3697. PubMed
6. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
7. Zou C, et al. 2020. Cell Rep. 33:108447. PubMed
8. Bachran C, et al. 2017. Sci Rep.. 10.1038/s41598-017-17948-0. PubMed
9. Nederhoff MGJ, et al. 2019. Auton Neurosci. 221:102580. PubMed
10. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
11. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
12. Yang J, et al. 2022. Biosci Rep. :. PubMed
13. Hameed AM, et al. 2020. Sci Rep. 5.229166667. PubMed
14. Cao Q, et al. 2018. Am J Physiol Renal Physiol. 314:F561. PubMed
15. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
16. Nguyen N, et al. 2022. iScience. 25:103679. PubMed
17. Zalacain M, et al. 2021. Mol Ther Oncolytics. 20:23. PubMed
18. Bernal S, et al. 2020. British Journal of Pharmacology. 178(3):564-581. PubMed
19. Lopez-Sanz L, et al. 2021. Clinical and Translational Medicine. 11(7):e463. PubMed
20. Ronkina N, et al. 2019. J Immunol. 203:2291. PubMed
21. Dave K et al. 2017. eLife. 6 pii: e23382. PubMed
22. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
23. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
24. Gautam J, et al. 2020. J Neuroinflammation. 17:103. PubMed
25. McCormick B, et al. 2019. J Immunol. 203:1579. PubMed
26. Peng V, et al. 2020. J Biol Chem. 295:14866. PubMed
27. Yang M, et al. 2020. Oncoimmunology. 9:1708064. PubMed
28. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
29. Pérez-Hernández M, et al. 2021. Front Physiol. 11:623190. PubMed
30. Hawila E, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.104. PubMed
31. Chen S, et al. 2018. Immunohorizons. 0.345138889. PubMed
32. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
33. Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed
34. Wang H, et al. 2021. Nat Commun. 12:4826. PubMed
35. Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed
36. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
37. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
38. Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed
39. Mori H, et al. 2015. Toxicol Pathol. 43: 883-889. PubMed
40. Telford W, et al. 2017. Cytometry A. 91:314. PubMed
41. Mainini F, et al. 2018. Nucleic Acid Ther. 28:225. PubMed
42. Arnold S, et al. 2008. Exp Biol Med. 233:860. PubMed
43. Umemoto T, et al. 2017. EMBO J. 36:2390. PubMed
44. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
45. Wicki S, et al. 2018. Int J Mol Sci. 1.266666667. PubMed
46. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
47. Enders M, et al. 2020. J Immunol. 204:87. PubMed
48. Piao Y, et al. 2012. Neuro Oncology. 14:1379. PubMed
49. Artz A, Butz S, Vestweber D 2016. Am J Physiol Renal Physiol. 311: F176 - F181. PubMed
50. Godoy-Calderón MJ, et al. 2018. Oncotarget. 8:11370. PubMed
51. Schuler CF, et al. 2020. Allergy. 75:2279. PubMed
52. Shevchenko MA, et al. 2018. J Immunol Res. 8:53. PubMed
53. Wang SS, et al. 2021. Cell Chemical Biology. 28(5):699-710.e5. PubMed
54. Wu Y, et al. 2020. Biol Reprod. 1213:102. PubMed
55. Parigi SM, et al. 2018. Sci Rep. 0.440277778. PubMed
56. Ford J, et al. 2019. Front Immunol. 2.502083333. PubMed
57. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
58. Zhang P, et al. 2022. Nat Commun. 13:1588. PubMed
59. Ritchie N, Ijaz U, and Evans T. 2017. BMC Genomics.. 10.1186/s12864-017-4215-3. PubMed
60. Nguyen CH, et al. 2020. Biomedicines. 8:. PubMed
61. Bogorodskiy AO, et al. 2020. Front Immunol. 11:298. PubMed
62. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
63. Ren AQ, et al. 2021. Front Pharmacol. 12:693298. PubMed
64. Ruiz-Fernandez de Cordoba B, et al. 2022. Cancer Discov. . PubMed
65. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
66. Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed
67. Lin Z, et al. 2021. Stem Cells. 39:240. PubMed
68. Hwang BJ, et al. 2019. Oncogene. 38:7491. PubMed
69. Lee YJ, et al. 2018. Front Microbiol. 9:83. PubMed
70. Satoh–Takayama N, et al. 2020. Immunity. 52(4):635-649. PubMed
71. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
72. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
73. Jin H, et al. 2021. Int J Mol Sci. 22:. PubMed
74. Heib T, et al. 2021. Cell Reports. 35(6):109102. PubMed
75. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
76. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
77. Winter C, et al. 2018. Cell Metab. 28:175. PubMed
78. Rios–Doria J, et al. 2017. Cancer Res. 77:2686. PubMed
79. Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed
80. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
81. Dubik M, et al. 2021. Front Neurosci. 15:682451. PubMed
82. Alrefai H, et al. 2016. Nat Commun. 7:11724. PubMed
83. Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed
84. He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed
85. Sparber F et al. 2019. British journal of pharmacology. 176(11):1728-1744 . PubMed

RRID

AB_313366 (BioLegend Cat. No. 108401)
AB_313367 (BioLegend Cat. No. 108402)

Antigen Details

Structure

21-25 kD

Distribution

Granulocytes, monocytes

Cell Type

Granulocytes, Monocytes, Neutrophils

Biology Area

Immunology, Innate Immunity

Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID

17067 View all products for this Gene ID 546644 View all products for this Gene ID

UniProt

View information about Ly-6G Ly-6C on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

Other Formats

Certificate of Analysis